Epigallocatechin gallate alleviates non-alcoholic fatty liver disease through the inhibition of the expression and activity of Dipeptide kinase 4
Article in Clinical Nutrition (June 2024)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease
Article in Metabolism (June 2024)
(−)-Epigallocatechin-3-O-gallate or (−)-epicatechin enhances lipid catabolism and antioxidant defense in common carp (Cyprinus carpio L.) fed a high-fat diet: Mechanistic insights from the AMPK/Sirt1/PGC-1α signaling pathway
Article in Aquaculture (June 2024)